REGENERON PHARMACEUTICALS, INC. (REGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 5B 10B 15B FY24: 14.2B FY25: 14.3B FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

0 1.5B 3B 4.5B FY24: 4B FY25: 3.6B FY24 FY25

Net Income Annual

0 2B 4B 6B FY24: 4.4B FY25: 4.5B FY24 FY25

Cost of Revenue Annual

0 150M 300M 450M FY18: 237.5M FY19: 402.8M FY18 FY19

Operating Cash Flow Annual

0 2B 4B 6B FY24: 4.4B FY25: 5B FY24 FY25

Free Cash Flow Annual

0 1.5B 3B 4.5B FY24: 3.7B FY25: 4.1B FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 40M 80M 120M FY24: 115.1M FY25: 108.6M FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 15.00 30.00 45.00 Q3 '24: 40.42 Q4 '24: 38.33 Q1 '25: 39.33 Q2 '25: 39.73 Q3 '25: 41.81 Q4 '25: 41.57 Q1 '26: 41.05 Q2 '26: 40.47 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.